{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:31:55Z","timestamp":1786516315887,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Acute myeloid leukemia (AML) treatments often cause profound immunosuppression, limiting immune-mediated control of residual disease. DIMATE, an ALDH1 inhibitor under clinical evaluation, induces aldehyde and redox stress in leukemic cells, but its impact on immune effector functions and tumor immunogenicity remains insufficiently defined. Here, we assessed the effects of DIMATE on human immune cells and AML models, including peripheral blood mononuclear cells, AML cell lines, and primary AML samples. DIMATE largely preserved selected immune effector functions at pharmacologically relevant concentrations, including T-cell activation, natural killer cell cytotoxicity, and phagocyte oxidative burst. In parallel, DIMATE induced pro-inflammatory and endoplasmic reticulum stress pathways in AML cells, upregulated co-stimulatory molecules, and promoted ICD-compatible features, including ecto-calreticulin exposure. These findings suggest that DIMATE may couple immune preservation with enhanced leukemic immunogenicity, supporting its potential for combination with immune-engaging therapies and strategies targeting measurable residual disease in AML, but also as a single agent capable of fostering a more immunostimulatory anti-leukemic context.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1876637","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:00:24Z","timestamp":1786514424000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["ALDH1 inhibition by DIMATE maintains immune responses and promotes immunogenic remodeling in AML"],"prefix":"10.3389","volume":"17","author":[{"given":"C\u00e9line","family":"Baier","sequence":"first","affiliation":[{"name":"Aix Marseille Univ, Theories and Approaches of Genomic Complexity (TAGC), INSERM UMR1090, Parc Scientifique de Luminy","place":["Marseille, France"]},{"name":"Advanced BioDesign, Parc Technologique de Lyon","place":["Saint Priest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Colle","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, Theories and Approaches of Genomic Complexity (TAGC), INSERM UMR1090, Parc Scientifique de Luminy","place":["Marseille, France"]},{"name":"Service H\u00e9matologie & Th\u00e9rapie Cellulaire, Assistance Publique-H\u00f4pitaux de Marseille (AP-HM), H\u00f4pital de la Conception","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Labiad","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, Theories and Approaches of Genomic Complexity (TAGC), INSERM UMR1090, Parc Scientifique de Luminy","place":["Marseille, France"]},{"name":"Advanced BioDesign, Parc Technologique de Lyon","place":["Saint Priest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Rihet","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, Theories and Approaches of Genomic Complexity (TAGC), INSERM UMR1090, Parc Scientifique de Luminy","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mileidys","family":"P\u00e9rez-Alea","sequence":"additional","affiliation":[{"name":"Advanced BioDesign, Parc Technologique de Lyon","place":["Saint Priest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Loriod","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, Transcriptomique et G\u00e9nomique de Marseille-Luminy (TGML) Platform, Parc Scientifique de Luminy","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Ceylan","sequence":"additional","affiliation":[{"name":"Advanced BioDesign, Parc Technologique de Lyon","place":["Saint Priest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffroy","family":"Venton","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, Theories and Approaches of Genomic Complexity (TAGC), INSERM UMR1090, Parc Scientifique de Luminy","place":["Marseille, France"]},{"name":"Service H\u00e9matologie & Th\u00e9rapie Cellulaire, Assistance Publique-H\u00f4pitaux de Marseille (AP-HM), H\u00f4pital de la Conception","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Martin","sequence":"additional","affiliation":[{"name":"Advanced BioDesign, Parc Technologique de Lyon","place":["Saint Priest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Costello","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, Theories and Approaches of Genomic Complexity (TAGC), INSERM UMR1090, Parc Scientifique de Luminy","place":["Marseille, France"]},{"name":"Service H\u00e9matologie & Th\u00e9rapie Cellulaire, Assistance Publique-H\u00f4pitaux de Marseille (AP-HM), H\u00f4pital de la Conception","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj0835","article-title":"Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V\u03b39V\u03b42 T cell-mediated antitumor immune response","volume":"13","author":"De Gassart","year":"2021","journal-title":"Sci Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.113860","article-title":"T-cell and natural killer cell therapies for hematologic Malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect","volume":"100","author":"Cruz","year":"2015","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01801","article-title":"Graft versus leukemia: current status and future perspectives","volume":"39","author":"O\u2019Neill","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.78","article-title":"Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors","volume":"6","author":"Venton","year":"2016","journal-title":"Blood Cancer J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1517\/17425255.4.6.697","article-title":"Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily","volume":"4","author":"Marchitti","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1021\/tx2005184","article-title":"Differences in susceptibility to inactivation of human aldehyde dehydrogenases by lipid peroxidation byproducts","volume":"25","author":"Yoval-S\u00e1nchez","year":"2012","journal-title":"Chem Res Toxicol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00435-0","article-title":"The role of ROS in tumour development and progression","volume":"22","author":"Cheung","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","article-title":"Targeting ROS in cancer: rationale and strategies","volume":"23","author":"Glorieux","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1184-9","article-title":"Dual disruption of aldehyde dehydrogenases 1 and 3 promotes functional changes in the glutathione redox system and enhances chemosensitivity in nonsmall cell lung cancer","volume":"39","author":"Rebollido-Rios","year":"2020","journal-title":"Oncogene"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00902-0","article-title":"Redox regulation of the immune response","volume":"19","author":"Morris","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12929-015-0194-3","article-title":"T cells and reactive oxygen species","volume":"22","author":"Belikov","year":"2015","journal-title":"J BioMed Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1432-8","article-title":"Blocking retinoic acid receptor-\u03b1 enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells","volume":"62","author":"Galvin","year":"2013","journal-title":"Cancer Immunol Immunother CII"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2016.06.021","article-title":"Anticancer metal drugs and immunogenic cell death","volume":"165","author":"Terenzi","year":"2016","journal-title":"J Inorg Biochem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02217-7","article-title":"Targeting the innate immune system in pediatric and adult AML","volume":"38","author":"Perzolli","year":"2024","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000533990","article-title":"Immunotherapy for acute myeloid leukemia: current trends, challenges, and strategies","volume":"147","author":"Chen","year":"2024","journal-title":"Acta Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0202","article-title":"Recent advances in immune-based therapies for acute myeloid leukemia","volume":"5","author":"Restelli","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"B21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1179\/1351000213Y.0000000044","article-title":"Redox regulation of the immune response","volume":"18","author":"Gostner","year":"2013","journal-title":"Redox Rep Commun Free Radic Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2011.4073","article-title":"Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease","volume":"18","author":"Kesarwani","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00478-8","article-title":"Redox regulation of immunometabolism","volume":"21","author":"Muri","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.it.2018.01.005","article-title":"Reactive oxygen species: involvement in T cell signaling and metabolism","volume":"39","author":"FranChina","year":"2018","journal-title":"Trends Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137585","article-title":"Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells","volume":"130","author":"Yang","year":"2020","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1969-z","article-title":"Upregulation of thioredoxin-1 in activated human NK cells confers increased tolerance to oxidative stress","volume":"66","author":"Mimura","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-024-01933-x","article-title":"Neutrophil extracellular traps in homeostasis and disease","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"10800","DOI":"10.1038\/s41467-025-65842-5","article-title":"Targeting leukemic stem cell biomechanics suppresses stemness and enhances NK cell-mediated immunotherapy","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 stimulation obviates innate sensors and drives T cell immunity in cancer","volume":"15","author":"Byrne","year":"2016","journal-title":"Cell Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045185","article-title":"CD80 and CD86 differentially regulate mechanical interactions of T-cells with antigen-presenting dendritic cells and B-cells","volume":"7","author":"Lim","year":"2012","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3421","article-title":"Odyssey: A first-in-human study of the aldehyde dehydrogenase (ALDH) inhibitor abd-3001 in patients with refractory\/relapsed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)","volume":"146","author":"Heiblig","year":"2025","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1876637\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:00:25Z","timestamp":1786514425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1876637\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2026.1876637"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1876637","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1876637"}}